Form 4: CERo Therapeutics Director Kathleen LaPorte Receives Stock Option Grant, Power of Attorney Filed

CERo Therapeutics Holdings, Inc. director Kathleen LaPorte was granted 9,326 stock options with an exercise price of $0.4454, part of a larger award vesting based on time and performance conditions, alongside the filing of a Limited Power of Attorney.

Summary

• Kathleen LaPorte, a Director of CERo Therapeutics Holdings, Inc., was granted 9,326 stock options on May 30, 2025.
• These options have an exercise price of $0.4454 per share and are set to expire on May 29, 2035.
• The 9,326 options represent the time-based portion, which is 1/3 of a larger total award of 27,979 shares.
• The time-based portion of the options will vest in equal monthly installments from July 4, 2025, through March 4, 2026.
• The remaining 2/3 of the total award (18,653 shares) is subject to specific performance conditions.
• A Limited Power of Attorney was executed by Kathleen LaPorte on June 2, 2025, appointing Andrew Albert Kucharchuk and Chris Ehrlich to execute and file SEC forms on her behalf.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of director compensation and a power of attorney. The grant of stock options is generally positive as it aligns interests, but there are no significant new positive or negative operational or financial details to warrant a high or low score. It's a neutral, expected corporate governance and compensation update.

Positives

• The grant of stock options to a director aligns her interests with those of shareholders, incentivizing long-term company performance and value creation.
• The combination of time-based and performance-based vesting conditions for the option award encourages both retention of the director and the achievement of strategic corporate goals.

Risks

• The ultimate value of the granted stock options is contingent on the future stock price of CERo Therapeutics, which is subject to market volatility and the company's operational performance.
• The performance-based portion of the stock option award may not vest if the specified performance conditions are not met, potentially reducing the total compensation received by the director.

Future Outlook

The vesting schedule for the granted stock options extends into March 2026, with a significant portion contingent on future performance conditions, indicating a focus on long-term strategic achievements.

Management Comments

• The Power of Attorney explicitly states that the attorneys-in-fact are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended.

Industry Context

This filing is a routine disclosure of director compensation in the form of equity, common practice in the biotechnology or pharmaceutical industry to align executive and director incentives with shareholder value creation and long-term company performance. The use of both time-based and performance-based vesting is a standard approach to executive compensation, balancing retention with achievement of specific corporate milestones, which are particularly relevant in R&D-intensive industries.

Comparison to Industry Standards

• The grant of stock options to a director, with a combination of time-based and performance-based vesting, is a common and standard practice for publicly traded companies, particularly within the biotechnology sector.
• This approach is widely adopted to align the interests of directors with long-term shareholder value creation and to incentivize the achievement of strategic milestones, consistent with compensation structures observed across the industry for companies at similar stages of development.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns her interests with shareholder value creation, as the options' value is tied to the company's stock performance.

Next Steps

• Continued vesting of the time-based stock options through March 4, 2026.
• Evaluation of performance conditions for the remaining portion of the stock option award.
• Ongoing compliance with SEC filing requirements by Kathleen LaPorte, facilitated by the appointed attorneys-in-fact.

Key Dates

Keywords

CERo Therapeutics, CERO, Stock Options, Form 4, SEC Filing, Director Compensation, Equity Grant, Vesting Schedule, Performance-Based Compensation, Power of Attorney, Insider Transaction Disclosure